Format
Sort by

Send to:

Choose Destination

Results: 3

Cited In for PubMed (Select 17848659)

1.

Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.

Rodríguez A, Reviriego J, Karamanos V, del Cañizo FJ, Vlachogiannis N, Drossinos V; ECLA Study Group.

Cardiovasc Diabetol. 2011 Feb 11;10:18. doi: 10.1186/1475-2840-10-18.

2.

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.

Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM.

BMJ. 2009 Aug 18;339:b2942. doi: 10.1136/bmj.b2942.

3.

Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.

Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C.

Vasc Health Risk Manag. 2008;4(4):753-68. Review.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk